A Qualitative Interview Study of General Practitioners’ Experiences of Managing Post-COVID-19 Syndrome DOI
Josefine Schulze,

Lennart Lind,

A. Rojas

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: April 25, 2024

Abstract Background The management of the long-term sequelae COVID-19 infection, known as post-COVID-19 syndrome (PCS), continues to challenge medical community, largely due a significant gap in understanding its aetiology, diagnosis and effective treatment. Aim To examine general practitioners’ (GPs) experiences caring for patients with PCS identify unmet care needs opportunities improvement. Design setting This study follows qualitative design, using in-depth semi-structured telephone interviews GPs ( N =31) from across Germany. Method Interviews were audio-recorded, transcribed verbatim analysed content analysis. Results Patients persistent symptoms after SARS-CoV-2 infection often consult their first point contact, typically resolving within weeks. While ongoing symptomatic is perceived be more common, relevance GP practices considerable given severe impact on patients’ functioning, social participation, substantial time required patient care. coordinate treatment, but face difficulties because unclear definition attributing symptoms, resulting cautious approach ICD-10 coding. Interviewees highlight lengthy diagnostic pathways barriers accessing specialist Conclusion findings confirm high functional limitations psychosocial burden central role suggests need further research health policy measures support navigating uncertainty, interprofessional communication limited evidence treatments. How this fits Post-COVID-19 has garnered attention healthcare, causes treatment challenges clinicians. illustrates symptom-driven approaches adopted by practitioners concerns about referring clinics. Greater collaboration sectors disciplines needed meet identified Research should also focus developing comprehensive differential protocols, address specific outpatient services.

Language: Английский

Long COVID: a clinical update DOI
Trisha Greenhalgh, Manoj Sivan,

Alice Perlowski

et al.

The Lancet, Journal Year: 2024, Volume and Issue: 404(10453), P. 707 - 724

Published: July 31, 2024

Language: Английский

Citations

103
Sleep disturbance in post COVID-19 conditions: Prevalence and quality of life DOI Creative Commons
Rimawati Tedjasukmana, Astri Budikayanti, Wardah Rahmatul Islamiyah

et al.

Frontiers in Neurology, Journal Year: 2023, Volume and Issue: 13

Published: Jan. 9, 2023

Post COVID-19 conditions are complaints and symptoms in patients with a history of probable or confirmed after 3 months the onset last at least 2 months. About 10–20% people may experience post conditions, one which is sleep disturbance. There wide range prevalence disturbances from 6% to more than 70%. An online survey various countries showed that 78.58% subjects had disturbances, including insomnia, sleep-disordered breathing, central disorders hypersomnolence, circadian rhythm sleep-wake disorders, parasomnias, sleep-related movement disorders. Sleep disturbance can be found starting weeks until 48 discharge having negative test results. Women aged < 50 years old severe infection reported worse outcome. Several mechanisms cause condition, namely persistent viral inflammation, immunity dysregulation, mitochondrial dysfunction. studies discovered was major problem affected different domains QoL conditions. Significant correlation between several dimensions SF-36 moderate-to-severe insomnia Therefore, affect patients' QoL, existence should concern period. Further research required determine based on agreed definition as well methods assess this condition its impact QoL.

Language: Английский

Citations

56
Association of Long COVID with mental health disorders: a retrospective cohort study using real-world data from the USA DOI Creative Commons
Yue Zhang, Vernon M. Chinchilli, Paddy Ssentongo

et al.

BMJ Open, Journal Year: 2024, Volume and Issue: 14(2), P. e079267 - e079267

Published: Feb. 1, 2024

Objectives Mental health disorders (MHD) rank third for US adult hospitalisations. Given the substantial prevalence of ‘Long COVID’ in SARS-CoV-2 survivors, this study aims to assess its association with increased MHD risk using extensive real-world data. Design A retrospective cohort propensity score matching was conducted. We used International Classification Diseases, 10th Revision codes identify individuals Long COVID status and COVID-19 histories. Multivariable stratified Cox proportional hazards regression analysis conducted determine MHD. Setting Data were sourced from TriNetX database, spanning records 1 October 2021 16 April 2023. Participants Two distinct cohorts established: one comprising diagnosed another no history or COVID-19. At start study, none participants had a recorded Primary secondary outcome measures The main interest composite diagnosis Secondary outcomes individual mental conditions. Results included 43 060 control without 4306 participants, demonstrating well-balanced distribution across all covariates. After adjusting 4 demographic factors 10 comorbidities, associated (adjusted HR, aHR 2.60; 95% CI 2.37 2.85). In subgroup analysis, major depression disorder (aHR 3.36; 2.82 4.00) generalised anxiety 3.44; 2.99 3.96). Conclusions large an incident impact is significant considering vast number patients COVID. Enhanced screening among survivors should be priority.

Language: Английский

Citations

12
Blood DNA methylation in post-acute sequelae of COVID-19 (PASC): a prospective cohort study DOI Creative Commons
Joseph Balnis, Andy Madrid, Lisa A. Drake

et al.

EBioMedicine, Journal Year: 2024, Volume and Issue: 106, P. 105251 - 105251

Published: July 17, 2024

Language: Английский

Citations

7
Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach DOI Creative Commons
Daniel O. Griffin

Open Forum Infectious Diseases, Journal Year: 2024, Volume and Issue: 11(9)

Published: Aug. 27, 2024

Abstract While the acute manifestations of infectious diseases are well known, in some individuals, symptoms can either persist or appear after period. Postviral fatigue syndromes recognized with other viral infections and described coronavirus disease 2019 (COVID-19). We have a growing number individuals that for weeks, months, years. Here, we share evidence regarding abnormalities associated postacute sequelae COVID-19 (PASC) therapeutics. describe physiological biochemical seen reporting PASC. several evidence-based interventions to offer patients. It is expected this understanding mechanisms driving PASC benefits certain therapeutics may not only lead better outcomes those but also potential treating postinfectious sequelae.

Language: Английский

Citations

7
Designing and optimizing clinical trials for long COVID DOI Creative Commons
Julia Moore Vogel,

Beth Pollack,

E. G. Spier

et al.

Life Sciences, Journal Year: 2024, Volume and Issue: 355, P. 122970 - 122970

Published: Aug. 13, 2024

Long COVID is a debilitating, multisystemic illness following SARS-CoV-2 infection whose duration may be indefinite. Over four years into the pandemic, little knowledge has been generated from clinical trials. We analyzed information available on ClinicalTrials.gov, and found that rigor focus of trials vary widely, majority test non-pharmacological interventions with insufficient evidence. highlight promising underway, encourage proliferation for treating other infection-associated chronic conditions illnesses (IACCIs). recommend several guidelines trials: First, pharmaceutical potentially curative, primary should prioritized, both drug repurposing new development pursued. Second, study designs rigorous accessible, e.g., triple-blinded randomized can conducted remotely, without participants needing to leave their homes. Third, studies have multiple comparator cohorts IACCIs such as myalgic encephalomyelitis (ME/CFS) dysautonomia, screen full spectrum symptomatology pathologies these illnesses. Fourth, consider inclusion/exclusion criteria an eye towards equity breadth representation, including all races, ethnicities, genders most impacted by COVID-19, levels severity. Fifth, involving patient-researchers in aspects brings immensely valuable perspectives will increase impact also efficient trial methods therapies parallel.

Language: Английский

Citations

4
Multidisciplinary Management Strategies for Long COVID: A Narrative Review DOI Open Access
Christian Prusinski, Dan Yan, Johana Klasová

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: May 1, 2024

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of infections to date and led a worldwide pandemic. Most patients had complete recovery from the infection, however, large number affected individuals experienced symptoms that persisted more than 3 months after diagnosis. These most commonly include fatigue, memory difficulties, brain fog, dyspnea, cough, other less common ones such as headache, chest pain, paresthesias, mood changes, muscle weakness, skin rashes, cardiac, endocrine, renal hepatic manifestations. The treatment this remains challenging. A multidisciplinary approach address combinations affecting multiple organ systems been widely adopted. This narrative review aims bridge gap surrounding broad approaches by providing an overview management strategies for long COVID conditions.

Language: Английский

Citations

3
Growth hormone treatment for neurologic symptoms of post‐acute sequelae of COVID‐19 DOI Creative Commons
Traver J. Wright, Melinda Sheffield‐Moore, Richard B. Pyles

et al.

Clinical and Translational Science, Journal Year: 2024, Volume and Issue: 17(6)

Published: June 1, 2024

Abstract Following SARS‐CoV‐2 infection, some patients develop lingering neurologic symptoms of post‐acute sequelae COVID‐19 (PASC) that commonly include fatigue and “brain fog.” PASC are also linked with reduced growth hormone (GH) secretion, but GH treatment has not been tested to relieve symptoms. We enrolled 13 adults peak stimulated secretion less than 10 ng/mL (glucagon stimulation) in a pilot study receive 9 months daily injections an additional 3 off‐treatment assessment. compared at baseline 12 assessed measures cognition, metabolism, body composition, physical performance over the first 6 treatment. Patient‐reported outcomes fatigue, quality life, sleep, mood were recorded timepoints 6, 9, months. was associated significantly improved scores for Brief Fatigue Inventory, Multidimensional Symptom Quality Life Assessment Growth Hormone Deficiency Adults, Profile Mood States, Beck Depression Inventory‐II, no significant change Pittsburgh Sleep Index. Six adjunct changes resting energy expenditure, or performance. Peak altered following altered.

Language: Английский

Citations

3
Long COVID-19 outcomes of patients with pre-existing dementia DOI Creative Commons
Roham Hadidchi,

Rachel Pakan,

Tharun T. Alamuri

et al.

Journal of Alzheimer s Disease, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 16, 2024

Although COVID-19 has been linked to worse acute outcomes in patients with some neurodegenerative disorders, its long-term impact on dementia remains unclear.

Language: Английский

Citations

3
Predictors of Cardiovascular Symptoms Among Long COVID Patients: Data from the Polish Long COVID Cardiovascular (PoLoCOV-CVD) Study DOI Open Access
Joanna Kapusta, Siamala Sinnadurai, Mateusz Babicki

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(3), P. 956 - 956

Published: Feb. 2, 2025

Background and aims: Long COVID symptoms persist globally, with a notable rise in cardiovascular disease (CVD) among COVID-19 survivors, including those without prior risk factors or hospitalizations. This study aims to identify predictors of cardiovascular-related symptoms. Methods: included subjects post-SARS-CoV-2 infections, categorizing them into three groups: non-Long (non-LC), (LC), (cardio-LC) as part the Polish Cardiovascular (PoLoCOV-CVD) collected between years 2020 2022, comprising 4000 participants. Chi-square tests logistic regression were used report prevalence determinants quality life cardio-LC, based on patient self-reported data comorbidities medications. Results: Of 704 patients analyzed, 71.9% female median age 54 (IQR: 45–64). Cardio-LC had statistically significant differences relative non-LC group terms blood pressure, elevated LDL cholesterol (p = 0.010), non-HDL 0.013). In addition, cardio-LC more likely be < 0.001) who exhibited psychological conditions, such sleep disturbances 0.001), anxiety depression compared group. However, multivariable analysis revealed that only gender remained an independent predictor associated (OR: 1.66, CI 1.12–2.46; OR: 1.742, 1.12–2.70) participants COVID. Conclusions: The positive association complications during highlights critical demographic deserve attention clinical practice.

Language: Английский

Citations

0